NovaBridge Biosciences · NASDAQ:NBP
NovaBridge Biosciences — I-Mab — Investor Presentation (June 2024)
25 slides from NovaBridge Biosciences's investor presentation, Jun 6, 2024
Slide 1: Transforming Potential into Reality
Transforming Potential into Reality I-Mab Biopharma June 5, 2024
Slide 2: Legal Disclaimer
2 Legal Disclaimer. This presentation has been prepared by I-Mab (the “Company”) solely for informational purposes. Certain of the information included herein was obtained from various sources, including certain third parties, and has not been independently verified by the Company. By viewing or acc
Slide 3: I-Mab is Well-positioned for Meaningful Value Creation
I-Mab is Well-positioned for Meaningful Value Creation A global biotech with an innovative portfolio and a healthy balance sheet 3 Uliledlimab (CD73) Givastomig (CLDN18.2 x 4-1BB) Ragistomig (PD-L1 x 4-1BB) Advancing an Innovative Pipeline NASDAQ-listed US-based Leadership Team Headquartered in Rock
Slide 4: Advancing a Differentiated and Commercially Attractive Pipeline
1. Co-developed with ABL Bio (also known as ABL503) 2. Global Data Epidemiology Data, Guidehouse legacy research Notes: CPI = checkpoint inhibitors; NSCLC = non-small cell lung cancer; PD-(L)1 refers to inhibitors of PD-L1 or PD-1; Ab = antibody; GC = gastric cancers; GEJ = gastroesophageal junction
Slide 5: Uliledlimab (targeting CD73)
Uliledlimab (targeting CD73) Initial development focused on newly diagnosed NSCLC with potential to expand across multiple indications in combination with immune checkpoint inhibitors Anti-CD73 CD73 Biology Key Advantages CD73 is the only enzyme that converts AMP into immunosuppressive adenosine Uli
Slide 6: CD73 is the Rate-Limiting Enzyme in the Adenosine Immunosuppression Pathway
CD73 is the Rate-Limiting Enzyme in the Adenosine Immunosuppression Pathway All AMP pathways converge at CD73 to generate adenosine 6 Advantages of targeting CD73 for cancer therapy: blocking CD73 activity leads to complete inhibition of the adenosine pathway. Known potential escape pathways (ATP, c
Slide 7: Uliledlimab: A Differentiated CD73 Antibody
CD73 enzyme activity inhibition Complete CD73 inhibition without the “hook effect” Uliledlimab: A Differentiated CD73 Antibody 7 Open conformation (inactive) Closed conformation (active) Oleclumab1 Intra-dimer binding mode Inter-dimer binding mode Open conformation (inactive) Closed conformation (ac
Slide 8: Uliledlimab Can Completely Inhibit CD73 Function in vitro Whereas Competitor Antibody Does Not
Complete inhibition by intra-dimer binding mode Partial inhibition by inter-dimer binding mode Uliledlimab Can Completely Inhibit CD73 Function in vitro Whereas Competitor Antibody Does Not Astra Zeneca is evaluating oleclumab in a Phase 3 study in patients with Stage III NSCLC Oleclumab (MEDI9447)
Slide 9: Inhibition of CD73 Activity & Tumor Growth is Dose-Dependent for Uliledlimab
Inhibition of CD73 Activity & Tumor Growth is Dose-Dependent for Uliledlimab 9 Inhibition of CD73 activity and tumor growth in vivo is limited by oleclumab’s hook effect biology Inhibition of CD73 activity and tumor growth in vivo by uliledlimab is dose-dependent 0 20 40 60 80 Tumor inhibition TGI (
Slide 10: Initial Anti-Tumor Data Supports Proof of Mechanism and Promising Safety
Initial safety profile of combination comparable to CPI monotherapy studies Initial Anti-Tumor Data Supports Proof of Mechanism and Promising Safety Notes: ORR = objective response rate; MTD = maximally tolerated dose; Q3W = every three weeks; AE = adverse events; CPI = checkpoint inhibitors; TRAEs
Slide 11: Most Tumors Decrease in Size
Most Tumors Decrease in Size Notes: Response definitions per iRECIST criteria. PR = partial response, SD = stable disease, PD = progressive disease, BOR = best overall response 11 Source: ASCO23 Poster Promising Early Phase 2 Data in Treatment Naïve NSCLC Patients
Slide 12: Most Responses are Durable
Most Responses are Durable 12 18 of 21 patients with an objective response remain on treatment with a median follow-up of 10.8 months Notes: Response definitions per iRECIST criteria. PR = partial response, SD = stable disease, PD = progressive disease, iUPD = unconfirmed progressive disease, NE not
Slide 13: Chemotherapy May Extend the Benefit of Uliledlimab Regardless of Baseline CD73 Expression
Emerging Data Indicate that Chemotherapy May Extend the Benefit of Uliledlimab to Patients Regardless of Baseline CD73 Expression 13 I-Mab plans to dose the first patient with uliledlimab in combination with chemotherapy and checkpoint inhibitor in newly diagnosed patients with advanced NSCLC in H2
Slide 14: Developing Uliledlimab as an Immunotherapy Combination of Choice
Favorable Safety Profile as Monotherapy and in Combination with CPIs Encouraging Phase 2 NSCLC Responses Support Use in Combination Studies Developing Uliledlimab as an Immunotherapy Combination of Choice 14 A 63% ORR observed in NSCLC patients with both high CD73 expression and PD-L1 TPS>1% suggest
Slide 15: Givastomig (targeting Claudin 18.2 and 4-1BB)
Molecular Design Key Differentiation Binding activity demonstrated across various levels of CLDN18.2 expression Exhibits CLDN18.2 binding even on low expressing tumor cells Higher-affinity binding to CLDN18.2 compared to reference antibody Zolbetuximab Localized T cell activation in TME to avoid 4-1
Slide 16: Early Phase Responses in Heavily Pretreated Patients Support Further Studies
Early Phase 1 Responses in Heavily Pretreated Patients Provides Compelling Support for Further Studies1 16 5 mg/Kg 8 mg/Kg 12 mg/Kg 15 mg/Kg > Treatment Ongoing Numbers: CLDN18.2 % PD SD PR Patient Overview: • 20 efficacy evaluable patients with CLDN18.2+ GC/GEJ/EAC • Three median lines of prior tre
Slide 17: Safety: Treatment Related AEs
Safety: Treatment Related AEs1 Preferred Term (all numbers are n(%)) Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 All Grades Nausea 10 (18.2) 3 (5.5) 0 0 0 13 (23.6) Vomiting 7 (12.7) 2 (3.6) 0 0 0 9 (16.4) Fatigue 7 (12.7) 1 (1.8) 0 0 0 8 (14.5) Anemia 1 (1.8) 4 (7.3) 1 (1.8) 0 0 6 (10.9) Abdominal pain
Slide 18: Givastomig Yields Better Monotherapy Responses Compared to Zolbetuximab Studies
Notes: Zolbetuximab (Astellas) is currently under review with the FDA; mAb = monoclonal antibody; ORR = overall response rate; DCR = disease control rate; CR = complete response; PR = partial response; SD = stable disease; GC = gastric cancers; GEJ = gastroesophageal junction; EAC = esophageal cance
Slide 19: Potential Differentiations of Givastomig from Other Claudin 18.2 Targeted Competitors
Potential Differentiations of Givastomig from Other Claudin 18.2 Targeted Competitors Givastomig Zolbetuximab ADCs MoA of Monotherapy CLDN18.2 dependent T cell activation in tumor 4-1BB agonism to increase T cell expansion in tumor and reinvigorate exhausted T cells Bi-specific antibody designed to
Slide 20: Unique Design To Enable Wide Use Plus Favorable Initial Safety Profile
Unique Design To Enable Wide Use Plus Favorable Initial Safety Profile Encouraging Responses in Previously Treated Patients, including Those with Low CLDN18.2 Dose Expansion Data and New Chemotherapy/Nivolumab Combo Planned for 2024 Unique Bispecific Design Properties and Monotherapy Data in Gastric
Slide 21: Ragistomig (ABL503/TJ-L14B, targeting PD-L1 and 4-1BB)
Molecular Design Key Differentiation Designed to treat PD-(L)1 expressing cancers Targeting PD-L1+ tumor cells and blocking PD-L1/PD-1 interaction PD-L1-dependent conditional 4-1BB activation via tumor site 4-1BB conditional activation with localized immune activation in TME Ragistomig (ABL503/TJ-L1
Slide 22: Unique Bispecific Design Properties and Monotherapy Data in R/R Patients
Unique Bispecific Design Properties and Monotherapy Data in R/R Patients 22 Objective responses seen in patients with progressive, locally advanced, or metastatic solid tumors that are relapsed or refractory following prior lines of treatment: • One Complete Response (CR), six Partial Responses (PR)
Slide 23: I-Mab Portfolio Projected to Substantially Advance: Key milestones in 2024
I-Mab Portfolio Projected to Substantially Advance Key milestones in 2024 23 Timing Program Milestone H1 2024 givastomig New triple combination dose expansion cohort began enrollment Givastomig/nivolumab/chemotherapy regimen (patients with gastric, GEJ, and esophageal cancers) H1 2024 ragistomig Pha
Slide 24: I-Mab is Well-positioned for Meaningful Value Creation
I-Mab is Well-positioned for Meaningful Value Creation A global biotech with an innovative portfolio and a healthy balance sheet 24 Uliledlimab (CD73) Givastomig (CLDN18.2 x 4-1BB) Ragistomig (PD-L1 x 4-1BB) Advancing an Innovative Pipeline NASDAQ-listed US-based Leadership Team Headquartered in Roc
Slide 25: Stay connected
Stay connected I-Mab Biopharma IR Contact Tyler Ehler Sr. Director, Investor Relations [email protected]